Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

Autor: M. Strobel, S. Herson, J. M. Lang, C. Picard-Dahan, Bruno Hoen, Dominique Salmon, Eric Billaud, P. Elinger, A. Laffeuillade, J. L. Touraine, M. Bentata, Renaud Verdon, Christine Katlama, P. Honoré, Claudine Duvivier, Sophie Abgrall, E. Arlet-Suau, K. Aleksandrowicz, Christian Trepo, Pascal Pugliese, T. Allegre, Jacques Gasnault, Jean-Pierre Daurès, C. Gaud, Xavier Duval, Emilie Lanoy, Anne Frésard, D. Quinsat, Valérie Potard, Jean-Pierre Clauvel, Jean-Michel Molina, J. M. Livrozet, P. Lecercq, B. Crickx, Elisabeth Bouvet, Hervé Tissot-Dupont, Y. Yasdanpanah, H. Laurichesse, M. Nezri, Christian Pradier, M. Brosseau, M. F. Maître, N. Desplanque, J. P. Delmont, Sophie Matheron, F. Lucht, D. Tisne-Dessus, Dominique Costagliola, François Raffi, P. De Truchis, Pierre Dellamonica, M. F. Thiercelin Legrand, Jean-Marc Lacombe, J. Soubeyrand, A. Simon, Cécile Goujard, E. Mortier, Isabelle Poizot-Martin, Hana Selinger-Leneman, Isabelle Ravaux, C. Jung, P. Sellier, Jean-Paul Viard, Christian Michelet, T. May, I. Auperin, J. L. Ecobichon, Valérie Martinez, J. P. Faller, P. Granet-Brunello, François Caron, M. Contant, Jean-Luc Berger, Laurence Lievre, Jacques Cadranel, Marie-Caroline Meyohas, C. Mayaud, Jacques Moreau, P. Choutet, André Boibieux, Patricia Enel, G. Beck-Wirth, Laurence Gérard, R. Pradinaud, Elisabeth Rouveix, M. Sobesky, H. Berthé, Francis Barin, J. M. Decazes, A. Galinier, Jacques Reynes, R. Cohen-Valensi, Patrick Yeni, T. Bommenel, Jean-Paul Stahl, C. Bazin, Vincent Jeantils, Pierluigi Blanc, Laurence Weiss, Daniel Vittecoq, Laurent Cotte, Pierre Tattevin, G. Pontonnier, David Rey, Sophie Grabar, Christian Rabaud, M. Diemer, D. Peyramond, Marguerite Guiguet, Pierre-Marie Girard, F. Pilorgé, S. Chapadaud, Jacques Gilquin, N. Jacquemet, Odile Launay, C. Chandemerle, P. Lesprit, Aba Mahamat, B. Taverne, F. Borsa-Lebas, G. Lepeu, Pascal Chavanet, Juliette Pavie, F. Gourdon, Jean-Albert Gastaut, Jean-François Delfraissy, Odile Picard, R. Fior, Alain Goudeau, P. Fraisse, M. A. Khuong, Lise Cuzin, Murielle Mary-Krause, L. Roudière, Boue F, V. Salomon, J. P. Esterni, N. Viget, D. Bonnet-Montchardon, Cédric Arvieux, André Cabié, Gilles Pialoux, François Bricaire, Jean-Luc Meynard, S. Tassi, Patrice Massip, Caroline Dupont, Christine Burty, F. Retornaz, D. Mechali, G. Rémy, Anne-Sophie Lascaux, L. Pelissier, J. M. Ruiz, F. Bissuel

Publikováno v: Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2011, 66 (8), pp.1869-77. ⟨10.1093/jac/dkr208⟩
Journal of Antimicrobial Chemotherapy, 2011, 66 (8), pp.1869-77. ⟨10.1093/jac/dkr208⟩

International audience; OBJECTIVES: To compare virological effectiveness in patients who continued on a virologically successful first-line boosted protease inhibitor (PI)-containing combination antiretroviral therapy (cART) regimen or who switched t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a54f541d3b14faf059faa18a9a23d8dd
https://hal.archives-ouvertes.fr/hal-00875284

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.